國立高雄大學圖資館 |

Language: English

Back

Personalized pathway-activated syste...

Huang, Gang.

Personalized pathway-activated systems imaging in oncologyprincipal and instrumentation /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Personalized pathway-activated systems imaging in oncologyedited by Tomio Inoue, David Yang, Gang Huang.
Reminder of title:	principal and instrumentation /
other author:	Inoue, Tomio.
Published:	Singapore :Springer Singapore :2017.
Description:	xii, 243 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	CancerImaging.
Online resource:	http://dx.doi.org/10.1007/978-981-10-3349-0
ISBN:	9789811033490$q(electronic bk.)

Personalized pathway-activated systems imaging in oncologyprincipal and instrumentation /
Personalized pathway-activated systems imaging in oncologyprincipal and instrumentation /[electronic resource] :edited by Tomio Inoue, David Yang, Gang Huang. - Singapore :Springer Singapore :2017. - xii, 243 p. :ill., digital ;24 cm.

Part 1: Chemical Biology Aspect -- Chapter 1: PET Radiotracers for Tumor Imaging (Ming Rong Zhang) -- Chapter 2. Theranostic tracers for pathway-activated systems in oncology (Lan V. Pham, Jerry L. Bryant, David Yang, and Richard J. Ford) -- Chapter 3. Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP (Chih-Hao K. Kao) - Part 2: Engineering and Instrumentation Aspect -- Chapter 4. OpenPET enabling PET imaging during radiotherapy (Taiga Yamaya and Hideaki Tashima) -- Chapter 5. High Resolution PET/CT development (Wai-Hoi Wong, and Yuxuan Zhang) -- Part 3: Social Aspect -- Chapter 6. Ethics, Regulations and Clinical Development of Precision Medicine: Activating with molecular imaging (Chieko Kurihara, and Tomio Inoue) -- Chapter 7. Optical Imaging: How far can we go (Wenbin Ma, Sara Herrera-Rodriguez, and Hector Martinez-Valdez) -- Part 4: Clinic Aspect -- Chapter 8. Applications of UIH High Resolution PET/CT in Zhongshan Hospital (Jun Zhou, Hongcheng Shi) -- Chapter 9. Clinical evaluation of focused high-resolution breast PET (Kanae Kawai Miyake, Yuji Nakamoto) -- Chapter 10. Recent Developments with Large-bore PET/CT (Tomohiro Kaneta, Tomio Inoue) -- Chapter 11. Copper-labeled radiopharmaceuticals in oncology (Hiroaki Kurihara) -- Chapter 12. PET radiopharmaceuticals in oncology beyond FDG (Shao-Li Song, Pan-Li Li, Gang Huang) -- Chapter 13. Molecular Imaging in Oncology: Challenges and Opportunities in 21st Century (Ya-Ming Li, Ya-Ming Li, David J. Yang, and Xue-Na Li) -- Chapter 14. Visualization of Apoptosis: Annexin V imaging (Skye Hsin-Hsien Yeh, Fan-Lin Kong, Ming-Hsien Lin)

This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists--molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.

ISBN: 9789811033490$q(electronic bk.)

Standard No.: 10.1007/978-981-10-3349-0doiSubjects--Topical Terms:

308847
Cancer
--Imaging.

LC Class. No.: RC270.3.D53

Dewey Class. No.: 616.9940754

Personalized pathway-activated systems imaging in oncologyprincipal and instrumentation /
LDR:04103nmm a2200313 a 4500 001 509384
003 DE-He213
005 20170302182546.0
006 m d
007 cr nn 008maaau
008 171121s2017 si s 0 eng d
020 $a 9789811033490$q(electronic bk.)
020 $a 9789811033483$q(paper)
024 7 $a 10.1007/978-981-10-3349-0 $2 doi
035 $a 978-981-10-3349-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RC270.3.D53
072 7 $a MMN $2 bicssc
072 7 $a MED080000 $2 bisacsh
082 0 4 $a 616.9940754 $2 23
090 $a RC270.3.D53 $b P467 2017
245 0 0 $a Personalized pathway-activated systems imaging in oncology $h [electronic resource] : $b principal and instrumentation / $c edited by Tomio Inoue, David Yang, Gang Huang.
260 $a Singapore : $b Springer Singapore : $b Imprint: Springer, $c 2017.
300 $a xii, 243 p. : $b ill., digital ; $c 24 cm.
505 0 $a Part 1: Chemical Biology Aspect -- Chapter 1: PET Radiotracers for Tumor Imaging (Ming Rong Zhang) -- Chapter 2. Theranostic tracers for pathway-activated systems in oncology (Lan V. Pham, Jerry L. Bryant, David Yang, and Richard J. Ford) -- Chapter 3. Optimization of Aseptic Production in PET Radiopharmaceuticals for Compliance to the Most Current GMP (Chih-Hao K. Kao) - Part 2: Engineering and Instrumentation Aspect -- Chapter 4. OpenPET enabling PET imaging during radiotherapy (Taiga Yamaya and Hideaki Tashima) -- Chapter 5. High Resolution PET/CT development (Wai-Hoi Wong, and Yuxuan Zhang) -- Part 3: Social Aspect -- Chapter 6. Ethics, Regulations and Clinical Development of Precision Medicine: Activating with molecular imaging (Chieko Kurihara, and Tomio Inoue) -- Chapter 7. Optical Imaging: How far can we go (Wenbin Ma, Sara Herrera-Rodriguez, and Hector Martinez-Valdez) -- Part 4: Clinic Aspect -- Chapter 8. Applications of UIH High Resolution PET/CT in Zhongshan Hospital (Jun Zhou, Hongcheng Shi) -- Chapter 9. Clinical evaluation of focused high-resolution breast PET (Kanae Kawai Miyake, Yuji Nakamoto) -- Chapter 10. Recent Developments with Large-bore PET/CT (Tomohiro Kaneta, Tomio Inoue) -- Chapter 11. Copper-labeled radiopharmaceuticals in oncology (Hiroaki Kurihara) -- Chapter 12. PET radiopharmaceuticals in oncology beyond FDG (Shao-Li Song, Pan-Li Li, Gang Huang) -- Chapter 13. Molecular Imaging in Oncology: Challenges and Opportunities in 21st Century (Ya-Ming Li, Ya-Ming Li, David J. Yang, and Xue-Na Li) -- Chapter 14. Visualization of Apoptosis: Annexin V imaging (Skye Hsin-Hsien Yeh, Fan-Lin Kong, Ming-Hsien Lin)
520 $a This comprehensive volume covers radiopharmaceuticals developed for pathway-directed systems in imaging and theranostic applications. We now are at the cutting edge of providing personalized treatment with increased use in oncology of these new radiopharmaceuticals. Trends in high-resolution instrumentation development, quality assurance systems and regulatory compliance for radiopharmaceuticals, clinical evaluation of radiopharmaceuticals, and benefits and pitfalls of the current clinical FDG PET are discussed. Radiopharmaceuticals are used for diagnosis of diseases of the central nervous and cardiovascular systems and for staging, restaging, and treatment planning for cancers. Nuclear biomarkers allow precise measurement of molecular pathways on a whole-body image upon administration of functional radiolabeled agents, and nuclear imaging agents have potential use in patient selection, pharmacokinetic, dosage-finding, and proof-of-concept studies. Nuclear imaging agents and hybrid instrumentation also provide sensitive and specific answers for differential responsiveness in therapeutic outcome. This book serves as a reference for moving the discovery and development of radiopharmaceuticals from the workbench to clinical applications. It thus benefits not only clinicians but also translational research scientists--molecular biologists, chemists, imaging scientists, pharmaceutical developers, physicists, and support staff.
650 0 $a Cancer $x Imaging. $3 308847
650 1 4 $a Medicine & Public Health. $3 273799
650 2 4 $a Nuclear Medicine. $3 275838
650 2 4 $a Oncology. $3 195181
700 1 $a Inoue, Tomio. $3 776169
700 1 $a Yang, David. $3 776170
700 1 $a Huang, Gang. $3 776171
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-981-10-3349-0
950 $a Medicine (Springer-11650)